DOCSLIB.ORG

Immunological Phenotype of LRBA Deficient Mice

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Immunological Phenotype of LRBA Deficient Mice Aus dem Centrum für Chronische Immundefizienz des Universitätsklinikums Freiburg im Breisgau Immunological phenotype of LRBA-deficient mice INAUGURAL – DISSERTATION zur Erlangung des Medizinischen Doktorgrades der Medizinischen Fakultät der Albert–Ludwigs–Universität Freiburg im Breisgau Vorgelegt 2018 von Fiona Isabel Jäger geboren in Karlsruhe Dekan: Prof. Dr. Norbert Südkamp 1. Gutachter: Prof. Dr. Bodo Grimbacher 2. Gutachter: Prof. Dr. Hanspeter Pircher Jahr der Promotion: 2019 1 Table of content List of figures ............................................................................................................................. 4 List of tables ............................................................................................................................... 6 Abbreviations ............................................................................................................................. 7 1. Introduction ............................................................................................................................ 9 1.1. Development and activation of B cells ........................................................................ 9 1.2. Development and activation of T cells .......................................................................... 11 1.3. Primary Immunodeficiencies ......................................................................................... 12 1.4. Characteristics of LPS-responsive beige-like anchor (LRBA) protein ......................... 13 1.5. LRBA shares domains with other BEACH family members ........................................ 14 1.6. LRBA deficiency ........................................................................................................... 16 1.6.1. Clinical and immunological phenotype of LRBA deficiency ................................. 16 1.6.2. Treatment options ................................................................................................... 18 1.7. The role of LRBA in lymphocytes – a pathogenesis hypothesis for LRBA deficiency 19 1.8. Objectives of this thesis ................................................................................................. 21 2. Materials and methods ......................................................................................................... 22 2.1. Materials ........................................................................................................................ 22 2.1.1. Devices and materials ............................................................................................. 22 2.1.2. Chemicals and reagents ........................................................................................... 23 2.1.3. Antibodies ............................................................................................................... 25 2.1.4. Buffers ..................................................................................................................... 26 2.1.5. Software .................................................................................................................. 27 2.2. Methods ......................................................................................................................... 28 2.2.1. Genotyping .............................................................................................................. 28 2.2.2. Sequencing .............................................................................................................. 30 2.2.3. Immunization .......................................................................................................... 30 2.2.4. Preparation of murine organs .................................................................................. 31 2.2.5. Cell staining for flow cytometry ............................................................................. 32 2.2.6. Western Blot ........................................................................................................... 34 5.2.7. ELISA ..................................................................................................................... 36 2.2.8. Histopathology analysis .......................................................................................... 36 2.2.9. Statistical analysis ................................................................................................... 37 3. Results .................................................................................................................................. 38 3.1. Genotyping of Lrba-/- mice ............................................................................................ 38 2 3.2. Sequencing of Lrba-/- mice ............................................................................................ 39 3.3. Lrba-/- mice do not express LRBA in the spleen ........................................................... 40 3.4. Lrba-/- mice present low body weight and signs of splenomegaly ................................ 41 3.5. Lrba-/- mice have a normal B cell compartment, except for low percentages of B-1a B cells ....................................................................................................................................... 44 3.6. Lrba-/- exhibit normal IgM and IgG titers in steady state conditions and increased IgA levels ..................................................................................................................................... 48 3.7. Lrba-/- mice have a normal T cell compartment ............................................................ 50 3.8. Intestinal histopathology of Lrba-/- mice showed no sign of inflammation, but young Lrba-/- mice had elevated plasma cell counts in the colon .................................................... 55 4. Discussion ............................................................................................................................ 60 4.1. Overall development and organomegaly in Lrba-/- mice ............................................... 61 4.2. B cell development in Lrba-/- mice ................................................................................ 62 4.3. Antibody production in Lrba-/- mice .............................................................................. 64 4.4. Investigation of the T cell compartment in Lrba-/- mice ................................................ 65 4.5. Investigation of intestinal histopathology in Lrba-/- mice ............................................. 66 4.6. Summary, limitations and outlook ................................................................................. 68 Abstract .................................................................................................................................... 70 Zusammenfassung .................................................................................................................... 71 References ................................................................................................................................ 72 List of publications ................................................................................................................... 79 Eidesstattliche Versicherung .................................................................................................... 80 Erklärung zum Eigenanteil/ Declaration of own contribution ................................................. 81 Acknowledgements .................................................................................................................. 83 3 List of figures Figure 1: Stages of B cell development.. ................................................................................. 10 Figure 2: Stages of T cell development .................................................................................... 11 Figure 3: Overview of the BDCP family. ................................................................................ 14 Figure 4: Distribution of major clinical presentations in LRBA-deficient patients ................. 18 Figure 5: CTLA-4 recycling is controlled by LRBA. CTLA-4, a competitor of CD28, binds CD80 and CD86, removing them from the cell surface through transendocytosis. ................. 20 Figure 6: Protein deficiency caused by Cre recombinase mediated excision of a LoxP flanked exon in Lrba. ............................................................................................................................ 28 Figure 7: Multiplex PCR strategy for mice genotyping. .......................................................... 29 Figure 8: Timeline of mouse immunization protocol. .............................................................. 30 Figure 9: Scheme of a horizontal electro blotting apparatus. ................................................... 35 Figure 10: Gel electrophoresis after genotyping PCR to distinguish Lrba+/+, Lrba+/-, and Lrba- /- mice........................................................................................................................................ 38 Figure 11: Lrba-/- mice lack exon 4 in sequencing analysis. .................................................... 39 Figure 12: Splenocytes (stimulated with 1ng/ml LPS overnight) of Lrba-/- mice do not express LRBA compared to Lrba+/+ and Lrba+/- mice. ........................................................................ 40 Figure 13: Lrba-/- mice presented with lower body weight compared to Lrba+/+ (p=0.1261) and Lrba+/- mice (p=0.8626)
Load more

Recommended publications
  • Diagnostic Interpretation of Genetic Studies in Patients with Primary
    AAAAI Work Group Report Diagnostic interpretation of genetic studies in patients with primary immunodeficiency diseases: A working group report of the Primary Immunodeficiency Diseases Committee of the American Academy of Allergy, Asthma & Immunology Ivan K. Chinn, MD,a,b Alice Y. Chan, MD, PhD,c Karin Chen, MD,d Janet Chou, MD,e,f Morna J. Dorsey, MD, MMSc,c Joud Hajjar, MD, MS,a,b Artemio M. Jongco III, MPH, MD, PhD,g,h,i Michael D. Keller, MD,j Lisa J. Kobrynski, MD, MPH,k Attila Kumanovics, MD,l Monica G. Lawrence, MD,m Jennifer W. Leiding, MD,n,o,p Patricia L. Lugar, MD,q Jordan S. Orange, MD, PhD,r,s Kiran Patel, MD,k Craig D. Platt, MD, PhD,e,f Jennifer M. Puck, MD,c Nikita Raje, MD,t,u Neil Romberg, MD,v,w Maria A. Slack, MD,x,y Kathleen E. Sullivan, MD, PhD,v,w Teresa K. Tarrant, MD,z Troy R. Torgerson, MD, PhD,aa,bb and Jolan E. Walter, MD, PhDn,o,cc Houston, Tex; San Francisco, Calif; Salt Lake City, Utah; Boston, Mass; Great Neck and Rochester, NY; Washington, DC; Atlanta, Ga; Rochester, Minn; Charlottesville, Va; St Petersburg, Fla; Durham, NC; Kansas City, Mo; Philadelphia, Pa; and Seattle, Wash AAAAI Position Statements,Work Group Reports, and Systematic Reviews are not to be considered to reflect current AAAAI standards or policy after five years from the date of publication. The statement below is not to be construed as dictating an exclusive course of action nor is it intended to replace the medical judgment of healthcare professionals.
    [Show full text]
  • Modeling Regulatory Network Topology Improves Genome-Wide
    bioRxiv preprint doi: https://doi.org/10.1101/2020.03.13.990010; this version posted March 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. LAST EDITED ON 2020-03-12 BY X.Z. 1 MODELING REGULATORY NETWORK TOPOLOGY IMPROVES 2 GENOME-WIDE ANALYSES OF COMPLEX HUMAN TRAITS 3 BY XIANG ZHU AND ZHANA DUREN AND WING HUNG WONG 4 Stanford University 5 Genome-wide association studies (GWAS) have cataloged many sig- 6 nificant associations between genetic variants and complex traits. How- 7 ever, most of these findings have unclear biological significance, because 8 they often have small effects and occur in non-coding regions. Integra- 9 tion of GWAS with gene regulatory networks addresses both issues by 10 aggregating weak genetic signals within regulatory programs. Here we 11 develop a Bayesian framework that integrates GWAS summary statis- 12 tics with regulatory networks to infer enrichments and associations si- 13 multaneously. Our method improves upon existing approaches by ex- 14 plicitly modeling network topology to assess enrichments, and by au- 15 tomatically leveraging enrichments to identify associations. Applying 16 this method to 18 human traits and 38 regulatory networks shows that 17 genetic signals of complex traits are often enriched in networks spe- 18 cific to trait-relevant tissue or cell types. Prioritizing variants within 19 enriched networks identifies known and new trait-associated genes re- 20 vealing novel biological and therapeutic insights.
    [Show full text]
  • LRBA Deficiency in a Patient with a Novel Homozygous Mutation Due
    CASE REPORT published: 16 October 2018 doi: 10.3389/fimmu.2018.02397 LRBA Deficiency in a Patient With a Novel Homozygous Mutation Due to Chromosome 4 Segmental Uniparental Isodisomy Pere Soler-Palacín 1,2, Marina Garcia-Prat 1,2, Andrea Martín-Nalda 1,2, Clara Franco-Jarava 2,3, Jacques G. Rivière 1,2, Alberto Plaja 4, Daniela Bezdan 5,6, Mattia Bosio 5,6, Mónica Martínez-Gallo 2,3, Stephan Ossowski 5,6,7 and Roger Colobran 2,3,4* 1 Pediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Universitari Vall d’Hebron, Vall d’Hebron Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain, 2 Jeffrey Modell Foundation Excellence Center, Barcelona, Spain, 3 Immunology Division, Department of Cell Biology, Physiology and Immunology, Hospital Universitari Vall d’Hebron, Vall d’Hebron Research Institute, Autonomous University of Barcelona, Barcelona, Spain, 4 Department of Clinical and Molecular Genetics, Hospital Universitari Vall d’Hebron, Barcelona, Spain, 5 Centre for Genomic Regulation, The Barcelona Institute of Science and Technology, Barcelona, Spain, 6 Universitat Pompeu Fabra, Barcelona, Spain, 7 Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany Edited by: LRBA deficiency was first described in 2012 as an autosomal recessive disorder Shen-Ying Zhang, caused by biallelic mutations in the LRBA gene (OMIM #614700). It was Rockefeller University, United States initially characterized as producing early-onset hypogammaglobulinemia, autoimmune Reviewed by: Satoshi Okada, manifestations, susceptibility to inflammatory bowel disease, and recurrent infection. School of Medicine, Hiroshima However, further reports expanded this phenotype (including patients without University, Japan hypogammaglobulinemia) and described LRBA deficiency as a clinically variable Bernice Lo, Sidra Medical and Research Center, syndrome with a wide spectrum of clinical manifestations.
    [Show full text]
  • 393LN V 393P 344SQ V 393P Probe Set Entrez Gene
    393LN v 393P 344SQ v 393P Entrez fold fold probe set Gene Gene Symbol Gene cluster Gene Title p-value change p-value change chemokine (C-C motif) ligand 21b /// chemokine (C-C motif) ligand 21a /// chemokine (C-C motif) ligand 21c 1419426_s_at 18829 /// Ccl21b /// Ccl2 1 - up 393 LN only (leucine) 0.0047 9.199837 0.45212 6.847887 nuclear factor of activated T-cells, cytoplasmic, calcineurin- 1447085_s_at 18018 Nfatc1 1 - up 393 LN only dependent 1 0.009048 12.065 0.13718 4.81 RIKEN cDNA 1453647_at 78668 9530059J11Rik1 - up 393 LN only 9530059J11 gene 0.002208 5.482897 0.27642 3.45171 transient receptor potential cation channel, subfamily 1457164_at 277328 Trpa1 1 - up 393 LN only A, member 1 0.000111 9.180344 0.01771 3.048114 regulating synaptic membrane 1422809_at 116838 Rims2 1 - up 393 LN only exocytosis 2 0.001891 8.560424 0.13159 2.980501 glial cell line derived neurotrophic factor family receptor alpha 1433716_x_at 14586 Gfra2 1 - up 393 LN only 2 0.006868 30.88736 0.01066 2.811211 1446936_at --- --- 1 - up 393 LN only --- 0.007695 6.373955 0.11733 2.480287 zinc finger protein 1438742_at 320683 Zfp629 1 - up 393 LN only 629 0.002644 5.231855 0.38124 2.377016 phospholipase A2, 1426019_at 18786 Plaa 1 - up 393 LN only activating protein 0.008657 6.2364 0.12336 2.262117 1445314_at 14009 Etv1 1 - up 393 LN only ets variant gene 1 0.007224 3.643646 0.36434 2.01989 ciliary rootlet coiled- 1427338_at 230872 Crocc 1 - up 393 LN only coil, rootletin 0.002482 7.783242 0.49977 1.794171 expressed sequence 1436585_at 99463 BB182297 1 - up 393
    [Show full text]
  • Clinical Immunology 160 (2015) 301–314
    Clinical Immunology 160 (2015) 301–314 Contents lists available at ScienceDirect Clinical Immunology journal homepage: www.elsevier.com/locate/yclim Application of whole genome and RNA sequencing to investigate the genomic landscape of common variable immunodeficiency disorders Pauline A. van Schouwenburg a,b,1, Emma E. Davenport a,c,1, Anne-Kathrin Kienzler a,b, Ishita Marwah a,b, Benjamin Wright a,c,MaryLucasa, Tomas Malinauskas d,HilaryC.Martina,c, WGS500 Consortium a,c,2, Helen E. Lockstone c, Jean-Baptiste Cazier c,e, Helen M. Chapel a,b, Julian C. Knight a,c,⁎,3, Smita Y. Patel a,b,⁎⁎,3 a Nuffield Department of Medicine, University of Oxford, Oxford, UK b Oxford NIHR Biomedical Research Centre, John Radcliffe Hospital, Oxford, UK c Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK d Cold Spring Harbor Laboratory, W. M. Keck Structural Biology Laboratory, Cold Spring Harbor, NY 11724, USA e Centre for Computational Biology, University of Birmingham, Haworth Building, B15 2TT Edgbaston, UK article info abstract Article history: Common Variable Immunodeficiency Disorders (CVIDs) are the most prevalent cause of primary antibody failure. Received 25 April 2015 CVIDs are highly variable and a genetic causes have been identified in b5% of patients. Here, we performed whole accepted with revision 20 May 2015 genome sequencing (WGS) of 34 CVID patients (94% sporadic) and combined them with transcriptomic profiling Available online 26 June 2015 (RNA-sequencing of B cells) from three patients and three healthy controls. We identified variants in CVID dis- ease genes TNFRSF13B, TNFRSF13C, LRBA and NLRP12 and enrichment of variants in known and novel disease Keywords: pathways.
    [Show full text]
  • Deleterious Mutations in LRBA Are Associated with a Syndrome of Immune Deficiency and Autoimmunity
    ARTICLE Deleterious Mutations in LRBA Are Associated with a Syndrome of Immune Deficiency and Autoimmunity Gabriela Lopez-Herrera,1,2 Giacomo Tampella,3,19 Qiang Pan-Hammarstro¨m,4,19 Peer Herholz,5,19 Claudia M. Trujillo-Vargas,1,6,19 Kanchan Phadwal,7 Anna Katharina Simon,7,8 Michel Moutschen,9 Amos Etzioni,10 Adi Mory,10 Izhak Srugo,10 Doron Melamed,10 Kjell Hultenby,4 Chonghai Liu,4,11 Manuela Baronio,3 Massimiliano Vitali,3 Pierre Philippet,12 Vinciane Dideberg,13 Asghar Aghamohammadi,14 Nima Rezaei,15 Victoria Enright,1 Likun Du,4 Ulrich Salzer,5 Hermann Eibel,5 Dietmar Pfeifer,16 Hendrik Veelken,17 Hans Stauss,1 Vassilios Lougaris,3 Alessandro Plebani,3 E. Michael Gertz,18 Alejandro A. Scha¨ffer,18 Lennart Hammarstro¨m,4 and Bodo Grimbacher1,5,* Most autosomal genetic causes of childhood-onset hypogammaglobulinemia are currently not well understood. Most affected individ- uals are simplex cases, but both autosomal-dominant and autosomal-recessive inheritance have been described. We performed genetic linkage analysis in consanguineous families affected by hypogammaglobulinemia. Four consanguineous families with childhood-onset humoral immune deficiency and features of autoimmunity shared genotype evidence for a linkage interval on chromosome 4q. Sequencing of positional candidate genes revealed that in each family, affected individuals had a distinct homozygous mutation in LRBA (lipopolysaccharide responsive beige-like anchor protein). All LRBA mutations segregated with the disease because homozygous individuals showed hypogammaglobulinemia and autoimmunity, whereas heterozygous individuals were healthy. These mutations were absent in healthy controls. Individuals with homozygous LRBA mutations had no LRBA, had disturbed B cell development, defec- tive in vitro B cell activation, plasmablast formation, and immunoglobulin secretion, and had low proliferative responses.
    [Show full text]
  • Supplementary Material Peptide-Conjugated Oligonucleotides Evoke Long-Lasting Myotonic Dystrophy Correction in Patient-Derived C
    Supplementary material Peptide-conjugated oligonucleotides evoke long-lasting myotonic dystrophy correction in patient-derived cells and mice Arnaud F. Klein1†, Miguel A. Varela2,3,4†, Ludovic Arandel1, Ashling Holland2,3,4, Naira Naouar1, Andrey Arzumanov2,5, David Seoane2,3,4, Lucile Revillod1, Guillaume Bassez1, Arnaud Ferry1,6, Dominic Jauvin7, Genevieve Gourdon1, Jack Puymirat7, Michael J. Gait5, Denis Furling1#* & Matthew J. A. Wood2,3,4#* 1Sorbonne Université, Inserm, Association Institut de Myologie, Centre de Recherche en Myologie, CRM, F-75013 Paris, France 2Department of Physiology, Anatomy and Genetics, University of Oxford, South Parks Road, Oxford, UK 3Department of Paediatrics, John Radcliffe Hospital, University of Oxford, Oxford, UK 4MDUK Oxford Neuromuscular Centre, University of Oxford, Oxford, UK 5Medical Research Council, Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, UK 6Sorbonne Paris Cité, Université Paris Descartes, F-75005 Paris, France 7Unit of Human Genetics, Hôpital de l'Enfant-Jésus, CHU Research Center, QC, Canada † These authors contributed equally to the work # These authors shared co-last authorship Methods Synthesis of Peptide-PMO Conjugates. Pip6a Ac-(RXRRBRRXRYQFLIRXRBRXRB)-CO OH was synthesized and conjugated to PMO as described previously (1). The PMO sequence targeting CUG expanded repeats (5′-CAGCAGCAGCAGCAGCAGCAG-3′) and PMO control reverse (5′-GACGACGACGACGACGACGAC-3′) were purchased from Gene Tools LLC. Animal model and ASO injections. Experiments were carried out in the “Centre d’études fonctionnelles” (Faculté de Médecine Sorbonne University) according to French legislation and Ethics committee approval (#1760-2015091512001083v6). HSA-LR mice are gift from Pr. Thornton. The intravenous injections were performed by single or multiple administrations via the tail vein in mice of 5 to 8 weeks of age.
    [Show full text]
  • Clinical, Immunological and Genetic Characteristic of Patients With
    ORIGINAL ARTICLE Clinical, immunological and genetic characteristic of patients with clinical phenotype associated to LRBA-deficiency in Colombia Características clínicas, inmunológicas y genéticas de pacientes con fenotipo clínico asociado a la deficiencia de LRBA en Colombia Catalina Martínez-Jaramillo1 , Sebastian Gutierrez-Hincapie1 , Julio César Orrego Arango2 , Gloria María Vásquez-Duque3 , Ruth María Erazo-Garnica3 , Jose Luis Franco1 and Claudia Milena Trujillo-Vargas1 1 Universidad de Antioquia, Facultad de Medicina, Grupo de Inmunodeficiencias Primarias, Medellin, Colombia, 2 Universidad de Antioquia, Grupo de Inmunología Celular e Inmunogenética, Medellin, Colombia, 3 Universidad de Antioquia, Programa de Posgrado, Reumatología Pediátrica, Medellin, Colombia *[email protected] Abstract Background: LPS-responsive beige -like anchor protein (LRBA) deficiency is a primary immunodeficiency OPEN ACCESS disease caused by loss of LRBA protein expression, due to biallelic mutations in LRBA Citation: Martínez-Jaramillo C, gene. LRBA deficiency patients exhibit a clinically heterogeneous syndrome. The Gutierrez-Hincapie S, Orrego main clinical complication of LRBA deficiency is immune dysregulation. Furthermore, AJC, Vásquez-Duque GM, Erazo- hypogammaglobulinemia is found in more than half of patients with LRBA-deficiency. To Garnica RM, Franco JL et al. date, no patients with this condition have been reported in Colombia Clinical, immunological and genetic characteristic of patients with clinical Objective: phenotype associated to LRBA- deficiency in Colombia.Colomb Med To evaluate the expression of the LRBA protein in patients from Colombia with clinical (Cali). 2019; 50(3): 176-91 http:// dx.org/1025100/cm.v50i3.3969 phenotype associated to LRBA-deficiency. Received: 25 Feb 2019 Methods: Revised: 28 Aug 2019 In the present study the LRBA-expression in patients from Colombia with clinical Accepted: 16 Sep 2019 phenotype associated to LRBA-deficiency was evaluated.
    [Show full text]
  • Interrogating Differences in Expression of Targeted Gene Sets to Predict Breast Cancer Outcome Sarah a Andres1, Guy N Brock2 and James L Wittliff1*
    Andres et al. BMC Cancer 2013, 13:326 http://www.biomedcentral.com/1471-2407/13/326 RESEARCH ARTICLE Open Access Interrogating differences in expression of targeted gene sets to predict breast cancer outcome Sarah A Andres1, Guy N Brock2 and James L Wittliff1* Abstract Background: Genomics provides opportunities to develop precise tests for diagnostics, therapy selection and monitoring. From analyses of our studies and those of published results, 32 candidate genes were identified, whose expression appears related to clinical outcome of breast cancer. Expression of these genes was validated by qPCR and correlated with clinical follow-up to identify a gene subset for development of a prognostic test. Methods: RNA was isolated from 225 frozen invasive ductal carcinomas,and qRT-PCR was performed. Univariate hazard ratios and 95% confidence intervals for breast cancer mortality and recurrence were calculated for each of the 32 candidate genes. A multivariable gene expression model for predicting each outcome was determined using the LASSO, with 1000 splits of the data into training and testing sets to determine predictive accuracy based on the C-index. Models with gene expression data were compared to models with standard clinical covariates and models with both gene expression and clinical covariates. Results: Univariate analyses revealed over-expression of RABEP1, PGR, NAT1, PTP4A2, SLC39A6, ESR1, EVL, TBC1D9, FUT8, and SCUBE2 were all associated with reduced time to disease-related mortality (HR between 0.8 and 0.91, adjusted p < 0.05), while RABEP1, PGR, SLC39A6, and FUT8 were also associated with reduced recurrence times. Multivariable analyses using the LASSO revealed PGR, ESR1, NAT1, GABRP, TBC1D9, SLC39A6, and LRBA to be the most important predictors for both disease mortality and recurrence.
    [Show full text]
  • Whole Exome Sequencing in Adult-Onset Hearing Loss Reveals A
    Lewis et al. BMC Medical Genomics (2018) 11:77 https://doi.org/10.1186/s12920-018-0395-1 RESEARCHARTICLE Open Access Whole exome sequencing in adult-onset hearing loss reveals a high load of predicted pathogenic variants in known deafness-associated genes and identifies new candidate genes Morag A. Lewis1,2, Lisa S. Nolan3, Barbara A. Cadge3, Lois J. Matthews4, Bradley A. Schulte4, Judy R. Dubno4, Karen P. Steel1,2† and Sally J. Dawson3*† Abstract Background: Deafness is a highly heterogenous disorder with over 100 genes known to underlie human non- syndromic hearing impairment. However, many more remain undiscovered, particularly those involved in the most common form of deafness: adult-onset progressive hearing loss. Despite several genome-wide association studies of adult hearing status, it remains unclear whether the genetic architecture of this common sensory loss consists of multiple rare variants each with large effect size or many common susceptibility variants each with small to medium effects. As next generation sequencing is now being utilised in clinical diagnosis, our aim was to explore the viability of diagnosing the genetic cause of hearing loss using whole exome sequencing in individual subjects as in a clinical setting. Methods: We performed exome sequencing of thirty patients selected for distinct phenotypic sub-types from well- characterised cohorts of 1479 people with adult-onset hearing loss. Results: Every individual carried predicted pathogenic variants in at least ten deafness-associated genes; similar findings were obtained from an analysis of the 1000 Genomes Project data unselected for hearing status. We have identified putative causal variants in known deafness genes and several novel candidate genes, including NEDD4 and NEFH that were mutated in multiple individuals.
    [Show full text]
  • Genes Associated with Common Variable Immunodeficiency: One Diagnosis to Rule Them All?
    See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/303747377 Genes associated with common variable immunodeficiency: one diagnosis to rule them all? Article in Journal of Medical Genetics · June 2016 Impact Factor: 6.34 · DOI: 10.1136/jmedgenet-2015-103690 READS 80 6 authors, including: Melissa Dullaers Bart N Lambrecht Ghent University Ghent University 49 PUBLICATIONS 1,114 CITATIONS 278 PUBLICATIONS 15,377 CITATIONS SEE PROFILE SEE PROFILE Elfride De Baere Filomeen Haerynck Ghent University Ghent University 159 PUBLICATIONS 3,452 CITATIONS 60 PUBLICATIONS 629 CITATIONS SEE PROFILE SEE PROFILE All in-text references underlined in blue are linked to publications on ResearchGate, Available from: Melissa Dullaers letting you access and read them immediately. Retrieved on: 14 June 2016 Downloaded from http://jmg.bmj.com/ on June 5, 2016 - Published by group.bmj.com JMG Online First, published on June 1, 2016 as 10.1136/jmedgenet-2015-103690 Review Genes associated with common variable immunodeficiency: one diagnosis to rule them all? Delfien J A Bogaert,1,2,3,4 Melissa Dullaers,1,4,5 Bart N Lambrecht,4,5 Karim Y Vermaelen,1,5,6 Elfride De Baere,3 Filomeen Haerynck1,2 1Clinical Immunology Research ABSTRACT dominant inheritance.2 So far, a monogenic cause Lab, Department of Pulmonary Common variable immunodeficiency (CVID) is a primary has been identified in 2–10% of patients with Medicine, Ghent University fi 24 Hospital, Ghent, Belgium antibody de ciency characterised by CVID. The majority of these genetic subtypes 2Department of Pediatric hypogammaglobulinaemia, impaired production of are very rare (figure 1 and table 1).
    [Show full text]
  • Application of Whole Genome and RNA Sequencing to Investigate the Genomic Landscape of Common Variable Immunodeficiency Disorders
    Europe PMC Funders Group Author Manuscript Clin Immunol. Author manuscript; available in PMC 2015 October 12. Published in final edited form as: Clin Immunol. 2015 October ; 160(2): 301–314. doi:10.1016/j.clim.2015.05.020. Europe PMC Funders Author Manuscripts Application of whole genome and RNA sequencing to investigate the genomic landscape of common variable immunodeficiency disorders Pauline A. van Schouwenburga,b,1, Emma E. Davenporta,c,1, Anne-Kathrin Kienzlera,b, Ishita Marwaha,b, Benjamin Wrighta,c, Mary Lucasa, Tomas Malinauskasd, Hilary C. Martina,c, WGS500 Consortiuma,c,2, Helen E. Lockstonec, Jean-Baptiste Cazierc,e, Helen M. Chapela,b, Julian C. Knighta,c,*,3, and Smita Y. Patela,b,**,3 aNuffield Department of Medicine, University of Oxford, Oxford, UK bOxford NIHR Biomedical Research Centre, John Radcliffe Hospital, Oxford, UK cWellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK dCold Spring Harbor Laboratory, W. M. Keck Structural Biology Laboratory, Cold Spring Harbor, NY 11724, USA eCentre for Computational Biology, University of Birmingham, Haworth Building, B15 2TT Edgbaston, UK Abstract Europe PMC Funders Author Manuscripts Common Variable Immunodeficiency Disorders (CVIDs) are the most prevalent cause of primary antibody failure. CVIDs are highly variable and a genetic causes have been identified in <5% of patients. Here, we performed whole genome sequencing (WGS) of 34 CVID patients (94% sporadic) and combined them with transcriptomic profiling (RNA-sequencing of B cells) from three patients and three healthy controls. We identified variants in CVID disease genes TNFRSF13B, TNFRSF13C, LRBA and NLRP12 and enrichment of variants in known and novel disease pathways.
    [Show full text]